The experimental colitis was developed in animal model (mice) and alleviated by means of L lactis but surprisingly activated when anti-TNF alpha ligand on recombinant L lactis was used in experiment
COBISS.SI-ID: 30102311
Based on the platform for the delivery of recombinant L lactis probiotics used for the treatment of Crohn diesase and ulcertive colitis we upgraded the delivery system by expression of ligands that successfuly bind shiga toxin and thus, demonstrated the general use of developed platform
COBISS.SI-ID: 29735975
By means of homologous anchoring sysetm of LysM that is expressed by soem probiotic strains we successfuly generated improved clones and demonstrated their use in GMO and non-GMO applications
COBISS.SI-ID: 28301607
Lactic acid bacteria (LAB) are food-grade hosts for surface display with potential applications in food and therapy. Alternative approaches to surface display on LAB would avoid the use of recombinant DNA technology and genetically-modified organism (GMO)-related regulatory requirements. Non-covalent surface display of proteins can be achieved by fusing them to various cell-wall binding domains, of which the Lysine motif domain (LysM) is particularly well studied. Fusion proteins have been isolated from recombinant bacteria or from their growth medium and displayed on unmodified bacteria, enabling heterologous surface display. This was demonstrated on non-viable cells devoid of protein content, termed bacteria-like particles, and on various species of genus Lactobacillus. Of the latter, Lactobacillus salivarius ATCC 11741 was recently shown to be particularly amenable for LysM-mediated display. Possible regulatory implications of heterologous surface display are discussed, particularly those relevant for the European Union.
COBISS.SI-ID: 3851633
Non-immunoglobulin (non-Ig) scaffolds are, in contrast to antibodies, small single-domain proteins that require no post-translational modification, often lack disulfide bonds, and can undergo straightforward multimerization. Among the 20 different types of non-Ig scaffolds, Adhirons, Alphabodies, Centyrins, Pronectins, Repebodies, Affimers, and Obodies have been introduced in the past4 years. 102 proteins have been specifically targeted by 139 different non-Ig scaffold binders. The most frequent application of non-Ig scaffolds is in the treatment and diagnosis of cancer and inflammatory diseases, and 10 non-Ig scaffolds have already been tested in clinical trials. Recently, non-Igscaffolds have often been used in research as structure determination chaperones, for intracellular monitoring of post-translational modifications, and as antibody alternatives for microscopy, flow cytometry, and Western blotting.
COBISS.SI-ID: 3851377